Dallah Healthcare Holding Co. reported a net profit of SAR 225.8 million for the fiscal year 2016, a leap of 37 percent year-on-year (YoY), backed by higher revenue from a rise in patient numbers, commencement of operations at the North Clinics and improvement in operating efficiency.
Item | 2015 | 2016 | Change |
---|---|---|---|
Revenues | 985.44 | 1,162.79 | 18.0 % |
Gross Income | 407.14 | 535.70 | 31.6 % |
Operating Income | 160.78 | 231.00 | 43.7 % |
Net Income | 165.06 | 224.71 | 36.1 % |
Average Shares | 90.00 | 90.00 | - |
EPS (Riyals) | 1.83 | 2.50 | 36.1 % |
Meanwhile, Q4 net profit declined 5 percent YoY to SAR 52 million, hurt by provisions for impairment in intangible asset and inventories.
The fourth-quarter profit dropped 15 percent when compared to the previous quarter.
Item | Q4 2015 | Q4 2016 | Change |
---|---|---|---|
Revenues | 276.50 | 316.24 | 14.4 % |
Gross Income | 116.81 | 151.01 | 29.3 % |
Operating Income | 57.01 | 57.96 | 1.7 % |
Net Income | 54.60 | 51.71 | (5.3 %) |
Average Shares | 90.00 | 90.00 | - |
EPS (Riyals) | 0.61 | 0.57 | (5.3 %) |
Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
---|---|---|---|---|---|---|
Q1 2016 | 285.03 | 18.6 % | 132.53 | 29.8 % | 61.90 | 56.1 % |
Q2 2016 | 288.35 | 17.6 % | 129.78 | 28.6 % | 59.34 | 66.2 % |
Q3 2016 | 273.17 | 22.0 % | 122.38 | 39.2 % | 51.80 | 96.4 % |
Q4 2016 | 316.24 | 14.4 % | 151.01 | 29.3 % | 57.96 | 1.7 % |
2016 | 1,162.79 | 18.0 % | 535.70 | 31.6 % | 231.00 | 43.7 % |
Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS Before XO Items |
---|---|---|---|---|---|---|
Q1 2016 | 58.07 | 21.4 % | 0.65 | (2.02) | 60.09 | 0.67 |
Q2 2016 | 54.14 | 51.0 % | 0.60 | (3.07) | 57.21 | 0.64 |
Q3 2016 | 60.80 | 127.0 % | 0.68 | 9.42 | 51.39 | 0.57 |
Q4 2016 | 51.71 | (5.3 %) | 0.57 | (6.00) | 57.71 | 0.64 |
2016 | 224.71 | 36.1 % | 2.50 | (1.68) | 226.39 | 2.52 |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
Q1 2016 | 42.51 % | 23.29 % | 17.20 % |
Q2 2016 | 43.49 % | 24.24 % | 18.50 % |
Q3 2016 | 44.66 % | 25.57 % | 19.88 % |
Q4 2016 | 46.07 % | 24.94 % | 19.47 % |
2016 | 46.07 % | 24.94 % | 19.47 % |
Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
---|---|---|---|---|
Q1 2016 | 90.00 | 1.95 | 1.97 | 16.15 |
Q2 2016 | 90.00 | 2.15 | 2.21 | 15.76 |
Q3 2016 | 90.00 | 2.53 | 2.48 | 16.26 |
Q4 2016 | 90.00 | 2.50 | 2.52 | 16.85 |
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
Q1 2016 | 27.46 | 27.14 | 3.31 |
Q2 2016 | 28.54 | 27.81 | 3.89 |
Q3 2016 | 21.29 | 21.71 | 3.31 |
Q4 2016 | 27.05 | 26.85 | 4.01 |
Q4 2016
Period | Medical Services | Medicine and Pharmaceutical Products |
---|---|---|
Q1 2016 | 276.15 | 8.88 |
Q2 2016 | 277.42 | 10.93 |
Q3 2016 | 265.04 | 8.13 |
Q4 2016 | 307.51 | 8.73 |
Item | Q4 2016 (e) | Q4 2016 (a) | Change |
---|---|---|---|
Average | 64.07 | 51.71 | (19.3 %) |
Item | Q4 2016 (e) | Q4 2016 (a) | Change |
---|---|---|---|
AlJazira Capital | 61.20 | 51.71 | (15.5) % |
OSOOL AND BAKHEET | 62.30 | 51.71 | (17.0) % |
Albilad Capital | 63.00 | 51.71 | (17.9) % |
Sico | 64.00 | 51.71 | (19.2) % |
Alistithmar Capital | 64.90 | 51.71 | (20.3) % |
Al Rajhi Capital | 69.00 | 51.71 | (25.1) % |
Current | |
Market Cap (M Riyal) | 15,921.84 |
Enterprise Value (EV) (M) | 17,841.44 |
Shares Outstanding ((M)) | 97.68 |
EPS ( Riyal) (TTM) | 4.54 |
Book Value (BV) ( Riyal) | 34.51 |
Par Value ( Riyal) | 10.00 |
Adjusted P/E (Last12) | 35.89 |
P/E (TTM) | 35.89 |
Price/book | 4.72 |
Return on Average Assets (%) (TTM) | 7.1 |
Return on Average Equity (%) (TTM) | 13.6 |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}